Literature DB >> 26847873

Bioanalytical challenges and improved detection of circulating levels of IL-13.

Fang Cai1, Hans Hornauer2, Kun Peng3, Cheryl A Schofield1, Heleen Scheerens1, Alyssa M Morimoto1.   

Abstract

BACKGROUND: IL-13 is a key mediator of type 2 inflammation-driven diseases. Circulating IL-13 levels are very low and challenging to detect reliably. We assessed the ability of immunoassays on the Erenna(®) and IMPACT platforms to measure serum IL-13 in asthma, idiopathic pulmonary fibrosis (IPF) and atopic dermatitis (AD) patients and in healthy controls (HC).
RESULTS: The Erenna IL-13 assay exhibited significant specificity issues and had limited ability to detect IL-13 in serum samples. The IMPACT IL-13 assay had excellent specificity and detected IL-13 in 100% of serum samples tested from asthma, IPF and AD patients and HC. Serum IL-13 levels were significantly elevated in asthma, IPF and AD patients, relative to HC.
CONCLUSION: The IMPACT IL-13 assay had fg/ml sensitivity and excellent specificity, enabling reliable detection of circulating levels of IL-13.

Entities:  

Keywords:  AD; IPF; asthma; sensitivity; serum IL-13; specificity; type 2 inflammation

Mesh:

Substances:

Year:  2016        PMID: 26847873     DOI: 10.4155/bio.15.254

Source DB:  PubMed          Journal:  Bioanalysis        ISSN: 1757-6180            Impact factor:   2.681


  6 in total

1.  Measurement of IL-17AA and IL-17FF as Pharmacodynamic Biomarkers to Demonstrate Target Engagement in the Phase I Study of MCAF5352A.

Authors:  Kun Peng; Yehong Wang; Ketevan Siradze; Rich Erickson; Saloumeh K Fischer; Tracy L Staton
Journal:  AAPS J       Date:  2018-12-13       Impact factor: 4.009

2.  Interleukin-13 in Asthma and Other Eosinophilic Disorders.

Authors:  Emma Doran; Fang Cai; Cécile T J Holweg; Kit Wong; Jochen Brumm; Joseph R Arron
Journal:  Front Med (Lausanne)       Date:  2017-09-19

3.  Overexpression of miR-155-5p Inhibits the Proliferation and Migration of IL-13-Induced Human Bronchial Smooth Muscle Cells by Suppressing TGF-β-Activated Kinase 1/MAP3K7-Binding Protein 2.

Authors:  Yujia Shi; Xingli Fu; Qi Cao; Zhengdao Mao; Yi Chen; Yun Sun; Zhiguang Liu; Qian Zhang
Journal:  Allergy Asthma Immunol Res       Date:  2018-05       Impact factor: 5.764

4.  Deleterious Role of Th9 Cells in Pulmonary Fibrosis.

Authors:  Kui Miao Deng; Xiang Sheng Yang; Qun Luo; Yi Xin She; Qing Yang Yu; Xiao Xiao Tang
Journal:  Cells       Date:  2021-11-17       Impact factor: 6.600

Review 5.  Type 2 inflammation in asthma and other airway diseases.

Authors:  Jorge Maspero; Yochai Adir; Mona Al-Ahmad; Carlos A Celis-Preciado; Federico D Colodenco; Pedro Giavina-Bianchi; Hani Lababidi; Olivier Ledanois; Bassam Mahoub; Diahn-Warng Perng; Juan C Vazquez; Arzu Yorgancioglu
Journal:  ERJ Open Res       Date:  2022-08-01

6.  Dose-dependent inactivation of airway tryptase with a novel dissociating anti-tryptase antibody (MTPS9579A) in healthy participants: A randomized trial.

Authors:  Sharon M Rymut; Siddharth Sukumaran; Gizette Sperinde; Meire Bremer; Joshua Galanter; Kenta Yoshida; Jordan Smith; Prajna Banerjee; Viyia Sverkos; Fang Cai; Verena Steffen; Lindsay M Henderson; Horace Rhee; Paula N Belloni; Joseph H Lin; Tracy L Staton
Journal:  Clin Transl Sci       Date:  2021-09-30       Impact factor: 4.689

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.